Guangzhou Baiyunshan Pharmaceutical General Factory, a unit of Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), received drug registration certificates for Tadalafil tablets from China's National Medical Products Administration.
The drug is mainly used for the treatment of male erectile dysfunction, according to a Shanghai bourse disclosure on June 6.
The certificate is valid until May 26, 2030, the disclosure said
The Chinese pharmaceutical company invested approximately 2.5 million yuan in research and development for the 2.5-milligram specification of the drug and 4.3 million yuan for the 5-milligram specification.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.